The current financial score of Bioventus Inc is 7.01. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 153.21M, representing a year-over-year increase of 3.76%, while its net profit experienced a year-over-year increase of 348.33%.
The current valuation score of Bioventus Inc is 8.17. Its current P/E ratio is 29.55, which is 685.63% below the recent high of 232.15 and 175.91% above the recent low of -22.43.
The current earnings forecast score of Bioventus Inc is 8.40. The average price target is 17.60, with a high of 19.00 and a low of 15.00.
The current price momentum score of Bioventus Inc is 3.49. Currently, the stock price is trading between the resistance level at 14.04 and the support level at 11.92, making it suitable for range-bound swing trading.
The current institutional shareholding score of Bioventus Inc is 7.00. The latest institutional shareholding proportion is 77.51%, representing a quarter-over-quarter decrease of 15.53%. The largest institutional shareholder is Chuck Royce, holding a total of 1.83M shares, representing 0.14% of shares outstanding, with 57.49% increase in holdings.
The current risk assessment score of Bioventus Inc is 6.37. The company's beta value is 0.67. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.